Johnson & Johnson has announced plans to showcase 16 presentations highlighting advances in its solid tumor pipeline at the European Society for Medical Oncology (ESMO) 2025 Congress. The presentations will cover head and neck, lung, bladder, and prostate cancers, focusing on both clinical data and pipeline developments. Notably, the first report of subcutaneous amivantamab will be presented, demonstrating clinical activity in recurrent or metastatic head and neck cancer. Additionally, a new analysis and recent U.S. FDA Fast Track designation for pasritamig in prostate cancer will be highlighted. The results are scheduled to be presented at ESMO 2025, with specific sessions for head and neck cancer data set for October 19 and 20, 2025.